Skip to main content
Clinical Trials/NCT02710916
NCT02710916
Completed
Not Applicable

SD-OCT Multimodal Analysis in GLaucoma

University Hospital, Bordeaux1 site in 1 country109 target enrollmentFebruary 22, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glaucoma
Sponsor
University Hospital, Bordeaux
Enrollment
109
Locations
1
Primary Endpoint
Evaluation of Bruch's Membrane Opening Minimum Rim Width
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Glaucoma is the first cause of irreversible blindness worldwide with more than 60 millions people affected in 2010. It is defined as a neurodegenerative disease characterized by a progressive loss of retinal ganglion cells (RGC), visual field deterioration and optic nerve excavation. Intraocular pressure (IOP) is the most common risk factor. Despite its severity, its impact on quality of life and an existing treatment that can delay visual field damages, there is no recommended strategy to screen the disease. Clinical evaluation of optic nerve head excavation performed either by ophthalmologists or glaucoma specialists is highly inter-observer dependent and limits its accuracy to diagnose glaucoma. Additionally, up to 30 to 40% of nerve fiber layer may be lost before detecting first visual field defects, thus making this tool not accurate enough for screening purposes.

Spectral-Domain Optical coherence tomography (SD-OCT) imaging technology allows precise and reproducible measurements of optic nerve head structures and retinal layers mainly related to the speed of acquisition and an axial resolution of 5 microns. New SD-OCT parameters have been developed to improve its diagnostic accuracy for glaucoma disease. The investigators therefore investigate performances of SD-OCT to discriminate glaucoma patients and controls. All subjects will undergo SD-OCT imaging (Spectralis™ OCT, Version 6.3, Heidelberg Engineering, Germany) and other study procedures in one single visit. All examinations performed on the subjects are non-significant risk.

Registry
clinicaltrials.gov
Start Date
February 22, 2016
End Date
December 21, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Bordeaux
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Normal Subjects
  • No history or evidence of retinal pathology or glaucoma
  • Normal Humphrey 24-2 Visual Field (VF) : A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%).
  • Intraocular pressure \< 21 mm Hg
  • Open angle (Shaffer's grading system)
  • Normal appearing Optic Nerve Hypoplasia (ONH) and Nerve Fiber Layer (NFL) : intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect
  • Symmetric ONH between left and right eyes: Cup-to-Disc Ratio (CDR) difference \< 0.2 in both vertical and horizontal dimensions
  • Inclusion Criteria: Perimetric Glaucoma
  • ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following:
  • diffuse or localized thinning of the rim

Exclusion Criteria

  • Refractive error of \> +6.00 D or \< -6.00 D (SE), +3,00 D for astigmatism
  • Diabetic retinopathy
  • Other diseases that may cause VF loss or optic disc abnormalities
  • Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil
  • Inability to perform reliably on automated VF testing
  • Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance). Minimum requirements are:
  • Retina completely included in image frame,
  • Quality Score ≥ 15 in the stored mean images,
  • Refusal of informed consent

Outcomes

Primary Outcomes

Evaluation of Bruch's Membrane Opening Minimum Rim Width

Time Frame: 1 day

Diagnostic accuracy of SD-OCT to discriminate perimetric, preperimetric glaucoma patients and control patients

Secondary Outcomes

  • Evaluation of Retinal Nerve Fiber Layer Thickness(1 day)

Study Sites (1)

Loading locations...

Similar Trials